CLAIM #6336 · Amgen Inc (AMGN) · 2026Q1 earnings call · Apr 30, 2026

“We expect to be able to open these studies back for enrollment shortly.”

James Bradner · EVP, R&D

How to check this claim

Look at: Enrollment status of the paused subcutaneous blinatumomab studies (Phase II registration-enabling adult/adolescent study and Phase Ib/II pediatric study)

It came true if: Company confirms studies have reopened for patient enrollment

Where: Company clinical trial disclosures (ClinicalTrials.gov status updates) or management commentary on subsequent earnings calls

Knowable after: 2026-07-31

In context

“% remission rates with manageable safety in adults with relapsed and refractory B-ALL. And so we are very encouraged by the efficacy seen with subcutaneous blin and are moving subcutaneous blin to earlier lines. As you shared, we have a potential registration-enabling Phase II initiated in adults and adolescents. We have a Phase Ib/II study of subcu blin as well initiated in pediatric patients there with relapsed and refractory and MRD-positive B-cell ALL. As you noted, we have paused some of these studies for enrollment. BiTEs are known to have inflammatory side effects. We prioritize patient safety, especially in the conduct of clinical investigation. And observing a handful of inflammatory reactions, we are at this moment collecting some patient data and having a dialogue with the FDA. We expect to be able to open these studies back for enrollment shortly. Robert A. Bradway: Next question, Julianne. Operator: Next question comes from Chris Schott from JPMorgan. Please go ahead. Your line is open. Christopher Thomas Schott: Great, thanks so much for the question. I just want to come back to Meritide. Sounds like some encouraging earlier-stage data on the titration. Are you able to provide any more color on what levels of vomiting and duration of vomiting you are seeing with the three-step titration from some of these earlier studies? Or if you cannot provide specific numbers, just maybe directionally, where that is shaking out versus a Wegovy or is that bound? Thanks so much. James E. Bradner: Yeah, Chris, thanks. The level of nausea and vomiting observed with three-step dose escalation is lower than we have seen before. Dose escalation work”

Verify independently

SEC filings for AMGN ↗ · Quote is verbatim from the 2026Q1 earnings call.